Sphingolipidoses – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Sphingolipidoses are a group of inherited metabolic storage disorders characterized by the accumulation of glycosphingolipids and phosphosphingolipids, which share a hydrophobic ceramide component in their structure. Hydrolases degrade these lipids within lysosomes, where sequential removal of their structural components occurs. Deficiencies in these hydrolases result in the inability to degrade complex lipids and accumulate ceramides, causing damage to various tissues and organs, particularly the central nervous system, and leading to symptoms such as neurodegeneration, mental retardation, and psychomotor retardation. It is classified based on the accumulation of specific lipids. The various sphingolipidoses are caused by genetic defects in the lysosomal hydrolases or their activator proteins, leading to impaired degradation of sphingolipids. A diagnosis is made through clinical examination, measurement of lysosomal enzyme activities in blood cells or skin fibroblasts, and genetic investigations or biopsy of accessible tissues.
·
Generally, sphingolipidoses occur in
approximately 1 out of 10,000 individuals.
Thelansis’s “Sphingolipidoses Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Sphingolipidoses treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Sphingolipidoses across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Sphingolipidoses Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment